Jacksonville, Fla. – June 16, 2026 – Today at the 129th Annual AOA Congress: Optometry’s Meeting, Johnson & Johnson announced an expanded parameter range up to -2.75D cylinder for ACUVUE OASYS 1-Day for Astigmatism contact lenses, helping more people with astigmatism enjoy excellent com-fort and clear, stable vision throughout the day.[5] The expanded portfolio of daily contact toric lenses will be available in the U.S. and Canada this summer, enabling optometrists to meet more patients’ needs than ever before.
Benefits of ACUVUE OASYS 1-Day for Astigmatism:
- Excellent, Stable Vision: BLINK STABILIZED Design helps the lens stays put, and helps provide clear, stable vision throughout the day, even with extensive head and eye movements.[5]
- Comfort: ACUVUE lenses are unbeaten in comfort in 47 clinical studies† and have fewer patient dropouts versus other manufacturers.[v]
- Accessibility: Expanded parameter range up to -2.75D cylinder helps optometrists to meet vision needs of more patients, with 3350 parameter combinations.[1]
“Expanding ACUVUE OASYS 1-Day for Astigmatism parameters is an important step in addressing the needs of people with astigmatism, which represents nearly half of all patients,” said Shawn Millerick, President, Americas, Vision, Johnson & Johnson. “By broadening parameter availability, we’re enabling Eye Care Professionals to fit more patients with daily contact lenses to enjoy excellent comfort and clear, stable vision throughout the day.”[5]
Astigmatism is a common vision condition affecting nearly half of all people,[6] caused by an irregular eye shape that can lead to blurry or distorted vision. Because it is often only partially corrected, many patients continue to experience distorted or blurred vision. For contact-lens wearers with astigmatism, it’s extremely important that their lenses stay in place when they blink or move their head for clear vision.
Only ACUVUE contact lenses feature BLINKSTABILIZED Design technology featuring four stability zones and a prism free optic zone. [++7,11,12] The contact lens is designed to realign naturally with every blink and orients quickly and stabilizes within minutes of insertion, helping to provide clear and stable vision throughout the day, even with extensive head and eye movements.[2,3,4]
This parameter expansion builds on recent ACUVUE portfolio enhancements [**8] and provide more options for doctors to fit patients with contact lenses:
- ACUVUE VITA for Astigmatism: Earlier this year, the parameter range was expanded for the ACUVUE monthly contact lens, allowing optometrists to fit nearly 96%[‡‡ of astigmatic patients,[9] offering around the clock coverage in 10 degree increments up to -2.75D cylinder.
ACUVUE OASYS MAX 1-Day for Astigmatism: Last year the ACUVUE OASYS MAX 1-Day for Astigmatism and ACUVUE OASYS MAX 1-Day MULTIFOCAL for Astigmatism lenses launched, making the ACUVUE OASYS MAX 1-Day Family of lenses the first and only complete daily disposable family of contact lenses on the market.[10¥]
To learn more about the ACUVUE OASYS 1-Day for Astigmatism contact lenses, patients can visit Acuvue.com and eye care professionals can visit JNJVisionPro.com.
IMPORTANT SAFETY INFORMATION
Important information for contact lens wearers: ACUVUE Contact Lenses are available by prescription only for vision correction. An eye care professional will determine whether contact lenses are right for you. Although rare, serious eye problems can develop while wearing contact lenses. To help avoid these problems, follow the wear and replacement schedule and the lens care instructions provided by your eye doctor. Do not wear contact lenses if you have an eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. If one of these conditions occurs, remove the lens and contact your eye doctor immediately. For more information on proper wear, care and safety, talk to your eye care professional, call 1-800-843-2020, or download the Patient Instruction Guides.
About Vision at Johnson & Johnson
Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients’ eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at clearvisionforyou.com, follow @JNJVision on X, Johnson & Johnson | Vision on LinkedIn, and @JNJVision on Facebook.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://www.jnjmedtech.com/en-US/. Follow us at @JNJMedTech and on LinkedIn.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to ACUVUE OASYS 1-Day for ASTIGMATISM. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
* ACUVUE® OASYS 1-Day for ASTIGMATISM: 3,350 SKUs; Precision1® for Astigmatism; 2,300 SKUs; Infuse ® One-Day for Astigmatism: 2,450 SKUs. Based on publicly available SKU information as of April 10, 2026.
†Clinical trial results posted on ClinicalTrials.gov, a website maintained by the NIH, were reviewed as of April 30, 2026. The 47 clinical trials evaluated subjective comfort as a primary or secondary endpoint for the ACUVUE® OASYS Brand family
v2024 US Growth Levers, n=8,000 respondents, significant difference in retention at 95% confidence.
++ Vertical heterophoria possibly caused by prism dissociation due to the presence of induced optical prism is a relevant factor for practitioners to consider when fitting toric contact lenses for monocular astigmats or those requiring a mix of toric soft contact lens designs.1,2 Clinical studies have not been done to fully characterize the clinical effects of differences in base down prism among different contact lenses. . **Rx range: -1.50 to -4.00DS inclusive, -0.75 to 1.50DC inclusive and axes within 180 ± 15 degrees or 90 ± 15 degrees.
[‡‡ Actual coverage is 95.5%
¥Full/complete family consists of sphere, multifocal, toric, and multifocal toric contact lenses.
© Johnson & Johnson and its affiliates 2026. All rights reserved.